Patents by Inventor Stephan Von Gunten

Stephan Von Gunten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD89 ACTIVATION IN THERAPY
    Publication number: 20170166640
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 15, 2017
    Applicants: CSL BEHRING AG, UNIVERSITÄT BERN
    Inventors: Stephan VON GUNTEN, Marc WEHRLI, Adrian ZÜRCHER, Sylvia MIESCHER
  • CD89 activation in therapy
    Patent number: 9522184
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 20, 2016
    Assignees: CSL BEHRING AG, UNIVERSITAT BERN
    Inventors: Stephan Von Gunten, Marc Wehrli, Adrian Zürcher, Sylvia Miescher
  • CD89 ACTIVATION IN THERAPY
    Publication number: 20130302345
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Application
    Filed: December 14, 2011
    Publication date: November 14, 2013
    Applicants: UNIVERSITÄT BERN, CSL BEHRING AG
    Inventors: Stephan Von Gunten, Marc Wehrli, Adrian Zürcher, Sylvia Miescher